Skip to content
ChickenStockChickenStock
ResearchTAK
Takeda Pharmaceutical logo

Takeda Pharmaceutical (TAK) stock

NYSE

$21.64+0.23%(+0.05)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · not confirmed · Financial period · Latest fiscal year

Latest fiscal-year financials · Computed in-house by ChickenStock

P/E

-74.42x

Net loss — not comparable

P/B

1.52x

P/S

2.51x

Find stocks with P/B ≤ 0.9×

Latest earnings

Recent results in a standard quarterly format were not found in SEC filings.

Some foreign companies file only annual or current reports, so quarterly figures may be missing.

See recent SEC filings →

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

22 SEC filings
  • Platford Giles RichardPresident, IBU · Nov 4, 2026Open-market sale55,617 shares · $1.2M
    Avg. price $20.9270,253 shares held after
  • Bitetti Teresa MariePresident, OBU · Nov 2, 2026Open-market sale46,609 shares · $974K
    Avg. price $20.89214,501 shares held after
  • Duprey Lauren RusckowskiChief Transformation Officer · Sep 14, 2026Open-market sale34,535 shares · $640K
    Avg. price $18.54191,522 shares held after
  • Plump Andrew StewartPresident, R&D · Sep 2, 2026Open-market sale116,191 shares · $2.1M
    Avg. price $18.49145,465 shares held after
  • Plump Andrew StewartPresident, R&D · Aug 19, 2026Open-market sale19,651 shares · $363K
    Avg. price $18.49261,656 shares held after
  • Greenway Nicola Deidre PetalChief Human Resources Officer · Aug 18, 2026Open-market sale12,980 shares · $235K
    Avg. price $18.113940,049 shares held after
  • Shannon Elaine MaryPres., Global Supply & Quality · Aug 11, 2026Open-market sale20,363 shares · $357K
    Avg. price $17.5567,311 shares held after
  • Plump Andrew StewartPresident, R&D · Aug 10, 2026Open-market sale165,393 shares · $2.8M
    Avg. price $17.1766,569 shares held after
  • Kim Julie So-YoungPresident and CEO · Aug 10, 2026Open-market sale89,090 shares · $1.5M
    Avg. price $17.1391,489 shares held after
  • Bitetti Teresa MariePresident, OBU · Aug 10, 2026Open-market sale50,012 shares · $855K
    Avg. price $17.1252,010 shares held after
  • Duprey Lauren RusckowskiChief Transformation Officer · Aug 10, 2026Open-market sale47,586 shares · $814K
    Avg. price $17.1226,057 shares held after
  • Greenway Nicola Deidre PetalChief Human Resources Officer · Aug 10, 2026Open-market sale41,377 shares · $722K
    Avg. price $17.44
    Show 3 price lots
    • 33,628 shares × $17.5067$589K
    • 6,774 shares × $17.1$116K
    • 975 shares × $17.5$17K
  • Platford Giles RichardPresident, IBU · Aug 10, 2026Open-market sale31,083 shares · $532K
    Avg. price $17.1315,838 shares held after
  • Furney Natalie Anne MarieGlobal General Counsel · Aug 10, 2026Open-market sale30,868 shares · $528K
    Avg. price $17.1204,298 shares held after
  • Ricci GabrieleChief Data & Tech. Officer · Aug 10, 2026Open-market sale25,088 shares · $429K
    Avg. price $17.1171,654 shares held after
  • Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev · Aug 10, 2026Open-market sale22,957 shares · $393K
    Avg. price $17.1176,977 shares held after
  • Pacheco Rhonda JanicePresident, U.S. Business Unit · Aug 10, 2026Open-market sale16,901 shares · $289K
    Avg. price $17.1182,507 shares held after
  • Farajallah Awny Samaan BotrosChief Medical Officer · Aug 10, 2026Open-market sale14,006 shares · $240K
    Avg. price $17.1116,177 shares held after
  • Ibrahim Ramy Riad AhmedPresident, PDT BU · Aug 10, 2026Open-market sale7,277 shares · $124K
    Avg. price $17.1102,588 shares held after
  • Shannon Elaine MaryPres., Global Supply & Quality · Aug 10, 2026Open-market sale3,978 shares · $68K
    Avg. price $17.163,333 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Takeda Pharmaceutical (TAK) stock information

NYSE

Takeda Pharmaceutical (TAK) is listed on NYSE. Its market capitalization is about $69.1B. On trailing-twelve-month earnings the P/E ratio is -74.42, and the P/B ratio is 1.52. Return on equity is -2%. These figures are computed in-house from official filings and are reference information only.

Takeda Pharmaceutical — frequently asked questions

What is the P/E ratio of Takeda Pharmaceutical (TAK)?
On a trailing-twelve-month basis, TAK trades at a P/E ratio of -74.42. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Takeda Pharmaceutical?
TAK has a market capitalization of about $69.1B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.